Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 291,337 | 423,308 | 347,559 | 286,497 | 193,618 |
| Marketable Securities | 2,073,015 | 2,018,477 | 1,628,269 | 1,629,213 | 1,527,619 |
| TOTAL | $2,371,770 | $2,448,362 | $1,985,671 | $1,929,092 | $1,733,666 |
| Non-Current Assets | |||||
| PPE Net | 108,068 | 112,175 | 115,851 | 120,831 | 124,926 |
| Investments And Advances | 0 | 0 | 0 | 28,412 | 0 |
| Other Non-Current Assets | 170,932 | 165,283 | 163,721 | 166,973 | 171,119 |
| TOTAL | $279,000 | $277,458 | $279,572 | $316,216 | $296,045 |
| Total Assets | $2,650,770 | $2,725,820 | $2,265,243 | $2,245,308 | $2,029,711 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 11,307 | 13,647 | 11,138 | 11,798 | 9,753 |
| Accrued Expenses | 70,772 | 75,570 | 90,520 | 87,608 | 74,453 |
| Other current liabilities | 16,982 | 13,113 | 13,113 | N/A | N/A |
| TOTAL | $132,896 | $136,286 | $149,120 | $118,957 | $104,362 |
| Non-Current Liabilities | |||||
| Long Term Debt | 586,198 | 585,470 | N/A | N/A | N/A |
| Deferred Revenues | 15,189 | 15,344 | 15,771 | 1,295 | 2,129 |
| Other Non-Current Liabilities | 185,125 | 189,508 | 194,310 | 198,046 | 201,901 |
| TOTAL | $771,323 | $774,978 | $194,310 | $210,369 | $214,224 |
| Total Liabilities | $904,219 | $911,264 | $343,430 | $329,326 | $318,586 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | N/A | 96,449 | 95,985 | 95,300 | 90,950 |
| Common Shares | 3,130 | 3,115 | 3,087 | 3,013 | 2,794 |
| Retained earnings | -2,161,636 | -2,070,482 | -1,947,551 | -1,816,938 | -1,710,497 |
| Other shareholders' equity | -4,689 | -2,001 | 4,761 | 4,926 | 3,979 |
| TOTAL | $1,746,551 | $1,814,556 | $1,921,813 | $1,915,982 | $1,711,125 |
| Total Liabilities And Equity | $2,650,770 | $2,725,820 | $2,265,243 | $2,245,308 | $2,029,711 |